Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis Among Preterm Infants

Abstract

In our model, the cost of prophylaxis against RSV for most subgroups of preterm infants was high relative to the benefits realized. Lower costs might permit the benefits of prophylaxis to be extended to additional groups of preterm infants.